ADC Therapeutics Provides LOTIS-7 Trial Updates on ZYNLONTA Combos for Relapsed/Refractory B-cell Lymphoma

A Phase 1b clinical trial known as LOTIS-7, which is assessing the combination of ZYNLONTA® (loncastuximab tesirine-lpyl) with bispecific antibodies for patients with certain types of non-Hodgkin lymphoma, has successfully completed its dose escalation without observing severe side effects. The trial, conducted by ADC Therapeutics SA, did not report any dose-limiting toxicities, cytokine release syndrome, or neurotoxicity syndrome in patients. Furthermore, there were indications of anti-tumor activity observed in the majority of participants. 

The study's second part, which focuses on dose expansion, has commenced. The drug ZYNLONTA, a CD19-directed antibody drug conjugate, has been cleared for use at three dosage levels (90, 120, and 150 µg/kg) in combination with glofitamab for patients with diffuse large B-cell lymphoma (DLBCL) in the second line or beyond. 

The company's Chief Medical Officer, Mohamed Zaki, expressed optimism about the potential of ZYNLONTA in combination therapies. The trial's lead investigator, Juan Pablo Alderuccio, highlighted the favorable toxicity profile of the treatment, which is crucial given the medical need for effective therapies for relapsed or refractory B-NHL. 

Ameet Mallik, CEO of ADC Therapeutics, noted the potential for broader use of ZYNLONTA in community settings due to the low incidence of cytokine release syndrome and neurotoxicity observed in the study. The LOTIS-7 trial is a global, multicenter study that includes three dosing arms and is divided into two parts: dose escalation and dose expansion. The trial is listed on clinicaltrials.gov with the identifier NCT04970901. 

ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Medicines Agency for the treatment of adult patients with r/r large B-cell lymphoma after at least two systemic therapies. ADC Therapeutics is a commercial-stage company specializing in antibody drug conjugates, with ZYNLONTA as one of their key products. The company is also engaged in the development of multiple ADCs in various stages of clinical and preclinical research. They are headquartered in Switzerland and maintain operations in several locations worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!